ENVB
Enveric Biosciences, Inc. (NASDAQ)
Healthcare — Biotechnology
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Price History
Fundamentals
| Market Cap | $6.04M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.06 |
| EPS (TTM) | $-22.74 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -183.12% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 43.0 |
| Beta | 1.10 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $17.64 |
| 52-Week Low | $1.26 |
| 50-Day Avg | $2.45 |
| 200-Day Avg | $4.15 |
| Avg Volume | $3.98M |
| Volume | 129.7K |
Performance Analysis
NEUTRALENVB presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:08 UTC
Back to Screener Export Report